LBRX NASDAQ
LB Pharmaceuticals Inc Common Stock
1W: +12.6%
1M: +12.2%
3M: +13.2%
YTD: +70.2%
$34.94
+0.16 (+0.46%)
After Hours: $34.91 (-0.02, -0.07%)
Weekly Expected Move ±7.9%
$29
$32
$35
$38
$41
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.0B
52W Range13.36-38.625
Volume289,888
Avg Volume248,450
Beta0.56
Dividend—
Analyst Ratings
Company Info
CEOHeather D. Turner
Employees27
SectorHealthcare
IndustryBiotechnology
IPO Date2025-09-11
Websitelbpharma.us
One Pennsylvania Plaza
New York, NY 10119
US
New York, NY 10119
US
212 605 0300
About LB Pharmaceuticals Inc Common Stock
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Latest News
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference
LB Pharmaceuticals Inc GAAP EPS of -$0.45
LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Recent Insider Trades
No insider trades found